

You Can Make New FSGS Treatments Possible

CLINICAL TRIALS FOR FSGS PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
EPPIK (Traverse)	FSGS, MCD, IgAN, IgAV, Alport Syndrome	1-17	Sparsentan	≥ 30
DUPLEX (ENROLLMENT COMPLETE) (Traverse)	FSGS	8-75	Sparsentan	≥ 30
THE PODO TRIAL (Pfizer)	FSGS	18+	PF-06730512	≥ 30
THE TRACTION-2 STUDY (Goldfinch Bio)	FSGS, treatment- resistant MCD, Lipoid Nephrosis, Diabetes Mellitus	18-75	GFB-887	≥ 30
STUDY OF VX-147 IN APOLI-MEDIATED PROTEINURIC KIDNEY DISEASE (Vertex)	Proteinuric Kidney Disease	18-60	VX-147	N/A
STUDY OF VX-147 IN APOLI-MEDIATED KIDNEY DISEASE (Vertex)	APOL1-Mediated FSGS	18-65	VX-147	≥ 30
AFFINITY (Chinook)	FSGS, IgAN, Alport Syndrome, DKD, Diabetic Nephropathy Type 2	18+	Atrasentan	≥ 30
STUDY OF BI 764198 IN FSGS (Boehringer Ingelheim)	FSGS	18-75	BI 764198	≥ 30
POST-APPROVAL STUDY OF LIPOSORBER LA-15 SYSTEM FOR PEDIATRIC & DRUG RESISTANT ADULT PATIENTS WITH FSGS (Kaneka)	Post-transplant recurrent FSGS or Primary FSGS	5-75	Liposorber LA-15 System	≥ 45 or post- transplant recurrence
TUMOR NECROSIS FACTOR INHIBITION IN FSGS AND TREATMENT-RESISTANT MCD (University of Michigan)	FSGS, MCD	6-70	adalimumab	> 45
STUDY OF VB119 IN STEROID-SENSITIVE PRIMARY MCD OR PRIMARY FSGS (ValenzaBio)	FSGS, MCD	18+	VB119	≥ 60
STUDY OF ANG-3070 IN PRIMARY GLOMERULAR DISEASE (Angion)	Glomerular Disease	18+	ANG-3070	≥ 40
STUDY OF BI 690517 ALONE AND IN COMBINATION WITH EMPAGLIFLOZIN IN DIABETIC AND NON-DIABETIC CKD (Boehringer Ingelheim)	Chronic Kidney Disease	18+	BI 690517	≥ 30 & < 90
STUDY TO TEST EFFECT OF DIFFERENT DOSES OF BI 685509 ON KIDNEY FUNCTION IN CKD WITHOUT DIABETES (Boehringer Ingelheim)	Chronic Kidney Disease	18+	BI 685509	≥ 20 & < 90
STUDY OF AZD5718 IN PROTEINURIC CKD (AstraZeneca)	Chronic Kidney Disease	18+	AZD5718, Dapagliflozin	20-75

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.



NEPHCURE
Kidney International

This is a living document and was last updated on 7/18/22

[Trial Table Updated Monthly on NephCure.org/TrialTable](https://NephCure.org/TrialTable)

You Can Make New FSGS Treatments Possible

CLINICAL TRIALS FOR FSGS PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
ZENITH-CKD (AstraZeneca)	Chronic Kidney Disease	18+	Zibotentan Dapagliflozin	≥ 20
EAGLE (Reata)	Chronic Kidney Disease, Alport Syndrome	12+	Bardoxolone methyl	≥ 20
FIONA - STUDY OF FINERENONE IN ADDITION TO AN ACEI OR ARB FOR CHILDREN 6 MONTHS TO < 18 YEARS OF AGE WITH CKD (Bayer)	Chronic Kidney Disease	6 months to 17 years	Finerenone (Kerendia, BAY94-8862)	≥ 30
FIND-CKD (Bayer)	Chronic Kidney Disease	18+	Finerenone (BAY94-8862)	≥ 25 and < 90
STUDY OF HECTOROL IN PEDIATRIC PATIENTS WITH CKD STAGES 3 AND 4 WITH HYPERPARATHYROIDISM NOT ON DIALYSIS (ENROLLMENT COMPLETE) (Sanofi)	Secondary Hyperparathyroidism Chronic Kidney Disease	5-18	Doxercalciferol (GZ427397)	15-59
SAFETY AND EFFICACY OF APR2020 IN CKD STAGE IV (Kibow)	Chronic Kidney Disease Stage IV	18-80	US-APR2020	15-29
PREVENTION OF ARTERIOVENOUS GRAFT THROMBOSIS AND SAFETY OF MK-2060 IN PATIENTS WITH ESRD RECEIVING HEMODIALYSIS (Merck Sharpe & Dohme)	End Stage Renal Disease & Kidney Failure	18+	MK-2060	N/A
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
FREEDOM-2 (Talaris)	De novo living donor transplant (3-12 months after transplant)	18+	FCR001	N/A
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18-75	Extracorporeal photopheresis	N/A
AUTOLOGOUS REGULATORY T CELL INFUSION AND ZORTRESS IN RENAL TRANSPLANT RECIPIENTS (Novartis)	De novo living donor transplant	18-65	Apheresis	N/A
STUDY OF VIB4920 AND BELATACEPT FOR PROPHYLAXIS OF ALLOGRAFT REJECTION IN KIDNEY TRANSPLANT (ENROLLMENT COMPLETE) (Horizon Therapeutics/Viela Bio)	De novo transplant	18-70	VIB4920 & Belatacept	N/A
T CELL MODULATION IN KIDNEY TRANSPLANTATION WITH BIOLOGIC BLOCKADE OF DUAL EFFECTOR PATHWAYS, CD28 & IL-6 (CTOT-24) (ENROLLMENT COMPLETE) (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
STEADFAST (Sangamo Therapeutics)	Kidney transplant rejection	18-70	TX200-TR101	N/A

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.



This is a living document and was last updated on 7/18/22

[Trial Table Updated Monthly on NephCure.org/TrialTable](https://NephCure.org/TrialTable)

You Can Make New MCD Treatments Possible

CLINICAL TRIALS FOR MCD PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
EPPIK (Traverse)	MCD, FSGS, IgAN, IgAV, Alport Syndrome	1-17	Sparsentan	≥ 30
THE TRACTION-2 STUDY (Goldfinch Bio)	Treatment-resistant MCD, FSGS, Lipoid Nephrosis, Diabetes Mellitus	18-75	GFB-887	≥ 30
TUMOR NECROSIS FACTOR INHIBITION IN FSGS AND TREATMENT-RESISTANT MCD (University of Michigan)	Treatment-resistant MCD, FSGS	6-70	adalimumab	> 45
STUDY OF VB119 IN STEROID-SENSITIVE PRIMARY MCD OR PRIMARY FSGS (ValenzaBio)	MCD, FSGS	18+	VB119	≥ 60
STUDY OF ANG-3070 IN PRIMARY GLOMERULAR DISEASE (Angion)	Glomerular Disease	18+	ANG-3070	≥ 40
STUDY TO TEST EFFECT OF DIFFERENT DOSES OF BI 685509 ON KIDNEY FUNCTION IN CKD WITHOUT DIABETES (Boehringer Ingelheim)	Chronic Kidney Disease	18+	BI 685509	≥ 20 & < 90
STUDY OF AZD5718 IN PROTEINURIC CKD (AstraZeneca)	Chronic Kidney Disease	18+	AZD5718, Dapagliflozin	20-75
EAGLE (Reata)	Chronic Kidney Disease, Alport Syndrome	12+	Bardoxolone methyl	≥ 20
FIONA - STUDY OF FINERENONE IN ADDITION TO AN ACEI OR ARB FOR CHILDREN 6 MONTHS TO < 18 YEARS OF AGE WITH CKD (Bayer)	Chronic Kidney Disease	6 months to 17 years	Finerenone (Kerendia, BAY94-8862)	≥ 30
FIND-CKD (Bayer)	Chronic Kidney Disease	18+	Finerenone (BAY94-8862)	≥ 25 and < 90
STUDY OF HECTOROL IN PEDIATRIC PATIENTS WITH CKD STAGES 3 AND 4 WITH HYPERPARATHYROIDISM NOT ON DIALYSIS (ENROLLMENT COMPLETE) (Sanofi)	Secondary Hyperparathyroidism Chronic Kidney Disease	5-18	Doxercalciferol (GZ427397)	15-59
SAFETY AND EFFICACY OF APR2020 IN CKD STAGE IV (Kibow)	Chronic Kidney Disease Stage IV	18-80	US-APR2020	15-29
PREVENTION OF ARTERIOVENOUS GRAFT THROMBOSIS AND SAFETY OF MK-2060 IN PATIENTS WITH ESRD RECEIVING HEMODIALYSIS (Merck Sharpe & Dohme)	End Stage Renal Disease & Kidney Failure	18+	MK-2060	N/A
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
FREEDOM-2 (Talaris)	De novo living donor transplant (3-12 months after transplant)	18+	FCR001	N/A

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.



NEPHCURE[®]
Kidney International

This is a living document and was last updated on 7/18/22.

Trial Table Updated Monthly on NephCure.org/TrialTable

You Can Make New MCD Treatments Possible

CLINICAL TRIALS FOR MCD PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18-75	Extracorporeal photopheresis	N/A
AUTOLOGOUS REGULATORY T CELL INFUSION AND ZORTRESS IN RENAL TRANSPLANT RECIPIENTS (Novartis)	De novo living donor transplant	18-65	Apheresis	N/A
STUDY OF VIB4920 AND BELATACEPT FOR PROPHYLAXIS OF ALLOGRAFT REJECTION IN KIDNEY TRANSPLANT (ENROLLMENT COMPLETE) (Horizon Therapeutics/Viela Bio)	De novo transplant	18-70	VIB4920 & Belatacept	N/A
T CELL MODULATION IN KIDNEY TRANSPLANTATION WITH BIOLOGIC BLOCKADE OF DUAL EFFECTOR PATHWAYS, CD28 & IL-6 (CTOT-24) (ENROLLMENT COMPLETE) (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
STEADFAST (Sangamo Therapeutics)	Kidney transplant rejection	18-70	TX200-TR101	N/A

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.

This is a living document and was last updated on 7/18/22.



NEPHCURE[®]
Kidney International

You Can Make New IgAN Treatments Possible

CLINICAL TRIALS FOR IGAN PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
EPPIK (Travere)	IgAN, FSGS, MCD, IgAV, Alport Syndrome	1-17	Sparsentan	≥ 30
SPARTAN (LEICESTER, UK) (Travere)	IgAN	18+	Sparsentan	≥ 30
PROTECT (ENROLLMENT COMPLETE) (Travere)	IgAN	18+	Sparsentan	≥ 30
AFFINITY (Chinook)	IgAN, FSGS, Alport Syndrome, DKD, Diabetic Nephropathy Type 2	18+	Atrasentan	≥ 30
ALIGN (Chinook)	IgAN	18+	Atrasentan	≥ 30
SAFETY & TOLERABILITY OF BION-1301 IN HEALTHY VOLUNTEERS & ADULTS WITH IGAN (Chinook)	IgAN	18+	BION-1301	≥ 30
VISIONARY (Otsuka)	IgAN	18+	Sibeprenlimab	≥ 30
SAFETY & EFFICACY OF VIS649 FOR IGAN (ENROLLMENT COMPLETE) (Visterra)	IgAN	18+	VIS649	≥ 45
STUDY OF BI 690517 ALONE AND IN COMBINATION WITH EMPAGLIFLOZIN IN DIABETIC AND NON-DIABETIC CKD (Boehringer Ingelheim)	IgAN, FSGS, MN, DKD, Hypertensive Kindey Disease	18+	BI 690517	≥ 30 and < 90
APPLAUSE-IGAN (Novartis)	IgAN	18+	LNP023	≥ 20
ORIGIN (ENROLLMENT COMPLETE) (Vera)	IgAN, Berger Disease	18+	Atacicept	≥ 30
NEFIGARD (ENROLLMENT COMPLETE) (Calliditas)	IgAN	18+	Nefecon	≥ 35
THE DISCOVERY TRIAL (ENROLLMENT COMPLETE) (Apellis)	IgAN, MN, C3G, Dense Deposit Disease, or Lupus Nephritis	18+	APL-2	≥ 30
SANCTUARY (Alexion)	IgAN, Lupus Nephritis	18-75	Ravulizumab	≥ 30
STUDY OF ALXN2050 IN IGAN & PROLIFERATIVE LUPUS NEPHRITIS (Alexion)	IgAN, Lupus Nephritis	18-75	ALXN2050	> 30

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.

This is a living document and was last updated on 7/18/22.



NEPHCURE
Kidney International

Trial Table Updated Monthly on NephCure.org/TrialTable

You Can Make New IgAN Treatments Possible

CLINICAL TRIALS FOR IGAN PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
TELITACEPT FOR INJECTION (RC18) IN IGAN (RemeGen)	IgAN	18-70	Telitacept	> 30
THE ARTEMIS-IGAN STUDY (Omeros)	IgAN	18+	Narsoplimab/ OMS721	≥ 30
IGNAZ (MorphoSys)	IgAN	18-80	Felzartamab	UPCR: ≥ 1.0
STUDY OF CEMDISIRAN IN ADULTS WITH IGAN (ENROLLMENT COMPLETE) (Alnylam)	IgAN	18-65	Cemdisiran	≥ 30
EFFECTIVENESS & SAFETY OF IONIS-FB-LRX IN IGAN (AUSTRALIA, CANADA, NEW ZEALAND) (Ionis)	IgAN	18-75	IONIS-FB-LRx	> 40
RENEW (ENROLLMENT COMPLETE) (BioCryst)	IgAN, C3G, MN	18+	BCX9930	≥ 50
SAFETY AND EFFICACY OF AT-1501 IN IGA NEPHROPATHY (Eledon)	IgAN	18-99	AT-1501	≥ 30
SAFETY AND TOLERABILITY OF MEZAGITAMAB (TAK-079) IN IGAN WITH STABLE BACKGROUND THERAPY (Takeda)	IgA Nephropathy, IgAV	18+	Mezagitamab	≥ 45
STUDY OF ANG-3070 IN PRIMARY GLOMERULAR DISEASE (Angion)	Glomerular Disease	18+	ANG-3070	≥ 40
STUDY TO TEST EFFECT OF DIFFERENT DOSES OF BI 685509 ON KIDNEY FUNCTION IN CKD WITHOUT DIABETES (Boehringer Ingelheim)	Chronic Kidney Disease	18+	BI 685509	≥ 20 & < 90
STUDY OF AZD5718 IN PROTEINURIC CKD (AstraZeneca)	Chronic Kidney Disease	18+	AZD5718, Dapagliflozin	20-75
ZENITH-CKD (AstraZeneca)	Chronic Kidney Disease	18+	Zibotentan Dapagliflozin	≥ 20
EAGLE (Reata)	Chronic Kidney Disease, Alport Syndrome	12+	Bardoxolone methyl	≥ 20
FIONA - STUDY OF FINERENONE IN ADDITION TO AN ACEI OR ARB FOR CHILDREN 6 MONTHS TO < 18 YEARS OF AGE WITH CKD (Bayer)	Chronic Kidney Disease	6 months to 17 years	Finerenone (Kerendia, BAY94-8862)	≥ 30
FIND-CKD (Bayer)	Chronic Kidney Disease	18+	Finerenone (BAY94-8862)	≥ 25 and < 90

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.

This is a living document and was last updated on 7/18/22.



NEPHCURE[®]
Kidney International

You Can Make New IgAN Treatments Possible

CLINICAL TRIALS FOR IGAN PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
STUDY OF HECTOROL IN PEDIATRIC PATIENTS WITH CKD STAGES 3 AND 4 WITH HYPERPARATHYROIDISM NOT ON DIALYSIS (ENROLLMENT COMPLETE) (Sanofi)	Secondary Hyperparathyroidism Chronic Kidney Disease	5-18	Doxercalciferol (GZ427397)	15-59
SAFETY AND EFFICACY OF APR2020 IN CKD STAGE IV (Kibow)	Chronic Kidney Disease Stage IV	18-80	US-APR2020	15-29
PREVENTION OF ARTERIOVENOUS GRAFT THROMBOSIS AND SAFETY OF MK-2060 IN PATIENTS WITH ESRD RECEIVING HEMODIALYSIS (Merck Sharpe & Dohme)	End Stage Renal Disease & Kidney Failure	18+	MK-2060	N/A
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
FREEDOM-2 (Talaris)	De novo living donor transplant (3-12 months after transplant)	18+	FCR001	N/A
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18-75	Extracorporeal photopheresis	N/A
AUTOLOGOUS REGULATORY T CELL INFUSION AND ZORTRESS IN RENAL TRANSPLANT RECIPIENTS (Novartis)	De novo living donor transplant	18-65	Apheresis	N/A
STUDY OF VIB4920 AND BELACEPT FOR PROPHYLAXIS OF ALLOGRAFT REJECTION IN KIDNEY TRANSPLANT (ENROLLMENT COMPLETE) (Horizon Therapeutics/Viela Bio)	De novo transplant	18-70	VIB4920 & Belatacept	N/A
T CELL MODULATION IN KIDNEY TRANSPLANTATION WITH BIOLOGIC BLOCKADE OF DUAL EFFECTOR PATHWAYS, CD28 & IL-6 (CTOT-24) (ENROLLMENT COMPLETE) (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
STEADFAST (Sangamo Therapeutics)	Kidney transplant rejection	18-70	TX200-TR101	N/A

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.

This is a living document and was last updated on 7/18/22.



NEPHCURE[®]
Kidney International

You Can Make New Membranous Nephropathy Treatments Possible

CLINICAL TRIALS FOR MEMBRANOUS PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
EFFICACY & SAFETY OF LNP023 COMPARED WITH RITUXIMAB IN ADULTS WITH IDIOPATHIC MN (Novartis)	MN	18+	LNP023, Rituximab	≥ 30
THE DISCOVERY TRIAL (ENROLLMENT COMPLETE) (Apellis)	MN, IgAN, C3G, Dense Deposit Disease, or Lupus Nephritis	18+	APL-2	≥ 30
A PHASE IB/2A STUDY OF VB119 IN PRIMARY MN (ValenzaBio)	MN	18+	VB119	≥ 45
NEW-PLACE (ENROLLMENT COMPLETE) (MorphoSys)	MN	18-80	MOR202	> 30
MONET (ITALY) (MorphoSys)	MN	18+	MOR202	> 30
M-PLACE (ENROLLMENT COMPLETE) (MorphoSys)	MN	18-80	MOR202	≥ 30
REBOOT (NIAID)	MN, Nephrotic Syndrome	18-75	Belimumab, Rituximab	≥ 30
EFFICACY & SAFETY OF OBINUTUZUMAB IN PARTICIPANTS WITH PRIMARY MN (Hoffmann-La Roche)	MN	18-75	Obinutuzumab	≥ 30
RENEW (ENROLLMENT COMPLETE) (BioCryst)	MN, IgAN, C3G	18+	BCX9930	≥ 50
STUDY OF ANG-3070 IN PRIMARY GLOMERULAR DISEASE (Angion)	Glomerular Disease	18+	ANG-3070	≥ 40
STUDY OF BI 690517 ALONE AND IN COMBINATION WITH EMPAGLIFLOZIN IN DIABETIC AND NON-DIABETIC CKD (Boehringer Ingelheim)	Chronic Kidney Disease	18+	BI 690517	≥ 30 & < 90
STUDY TO TEST EFFECT OF DIFFERENT DOSES OF BI 685509 ON KIDNEY FUNCTION IN CKD WITHOUT DIABETES (Boehringer Ingelheim)	Chronic Kidney Disease	18+	BI 685509	≥ 20 & < 90
STUDY OF AZD5718 IN PROTEINURIC CKD (AstraZeneca)	Chronic Kidney Disease	18+	AZD5718, Dapagliflozin	20-75
ZENITH-CKD (AstraZeneca)	Chronic Kidney Disease	18+	Zibotentan Dapagliflozin	≥ 20
EAGLE (Reata)	Chronic Kidney Disease, Alport Syndrome	12+	Bardoxolone methyl	≥ 20

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.



NEPHCURE[®]
Kidney International

This is a living document and was last updated on 7/18/22.

[Trial Table Updated Monthly on NephCure.org/TrialTable](https://NephCure.org/TrialTable)

You Can Make New Membranous Nephropathy Treatments Possible

CLINICAL TRIALS FOR MEMBRANOUS PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
FIONA - STUDY OF FINERENONE IN ADDITION TO AN ACEI OR ARB FOR CHILDREN 6 MONTHS TO < 18 YEARS OF AGE WITH CKD (Bayer)	Chronic Kidney Disease	6 months to 17 years	Finerenone (Kerendia, BAY94-8862)	≥ 30
FIND-CKD (Bayer)	Chronic Kidney Disease	18+	Finerenone (BAY94-8862)	≥ 25 and < 90
STUDY OF HECTOROL IN PEDIATRIC PATIENTS WITH CKD STAGES 3 AND 4 WITH HYPERPARATHYROIDISM NOT ON DIALYSIS (ENROLLMENT COMPLETE) (Sanofi)	Secondary Hyperparathyroidism Chronic Kidney Disease	5-18	Doxercalciferol (GZ427397)	15-59
SAFETY AND EFFICACY OF APR2020 IN CKD STAGE IV (Kibow)	Chronic Kidney Disease Stage IV	18-80	US-APR2020	15-29
PREVENTION OF ARTERIOVENOUS GRAFT THROMBOSIS AND SAFETY OF MK-2060 IN PATIENTS WITH ESRD RECEIVING HEMODIALYSIS (Merck Sharpe & Dohme)	End Stage Renal Disease & Kidney Failure	18+	MK-2060	N/A
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
FREEDOM-2 (Talaris)	De novo living donor transplant (3-12 months after transplant)	18+	FCR001	N/A
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18-75	Extracorporeal photopheresis	N/A
AUTOLOGOUS REGULATORY T CELL INFUSION AND ZORTRESS IN RENAL TRANSPLANT RECIPIENTS (Novartis)	De novo living donor transplant	18-65	Apheresis	N/A
STUDY OF VIB4920 AND BELATACEPT FOR PROPHYLAXIS OF ALLOGRAFT REJECTION IN KIDNEY TRANSPLANT (ENROLLMENT COMPLETE) (Horizon Therapeutics/Viela Bio)	De novo transplant	18-70	VIB4920 & Belatacept	N/A
T CELL MODULATION IN KIDNEY TRANSPLANTATION WITH BIOLOGIC BLOCKADE OF DUAL EFFECTOR PATHWAYS, CD28 & IL-6 (CTOT-24) (ENROLLMENT COMPLETE) (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
STEADFAST (Sangamo Therapeutics)	Kidney transplant rejection	18-70	TX200-TR101	N/A

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.

This is a living document and was last updated on 7/18/22.



NEPHCURE
Kidney International

You Can Make New C3G Treatments Possible

CLINICAL TRIALS FOR C3G PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
APPEAR-C3G (Novartis)	C3G	18-60	LNP023	≥ 30
VALIANT (Apellis)	C3G, IC-MPGN, C3GN, DDD, MPGN	12+	Pegcetacoplan	≥ 30
THE NOBLE STUDY (Apellis)	C3G, C3GN, DDD, MPGN, or IC-MPGN that has recurred after kidney transplant	18+	Pegcetacoplan	≥ 15
THE DISCOVERY TRIAL (ENROLLMENT COMPLETE) (Apellis)	C3G, Dense Deposit Disease, IgAN, MN, or Lupus Nephritis	18+	APL-2	≥ 30
RENEW (ENROLLMENT COMPLETE) (BioCryst)	C3G, MN, IgAN	18+	BCX9930	≥ 50
STUDY TO TEST EFFECT OF DIFFERENT DOSES OF BI 685509 ON KIDNEY FUNCTION IN CKD WITHOUT DIABETES (Boehringer Ingelheim)	Chronic Kidney Disease	18+	BI 685509	≥ 20 & < 90
STUDY OF AZD5718 IN PROTEINURIC CKD (AstraZeneca)	Chronic Kidney Disease	18+	AZD5718, Dapagliflozin	20-75
ZENITH-CKD (AstraZeneca)	Chronic Kidney Disease	18+	Zibotentan Dapagliflozin	≥ 20
EAGLE (Reata)	Chronic Kidney Disease, Alport Syndrome	12+	Bardoxolone methyl	≥ 20
FIONA - STUDY OF FINERENONE IN ADDITION TO AN ACEI OR ARB FOR CHILDREN 6 MONTHS TO < 18 YEARS OF AGE WITH CKD (Bayer)	Chronic Kidney Disease	6 months to 17 years	Finerenone (Kerendia, BAY94-8862)	≥ 30
FIND-CKD (Bayer)	Chronic Kidney Disease	18+	Finerenone (BAY94-8862)	≥ 25 and < 90
STUDY OF HECTOROL IN PEDIATRIC PATIENTS WITH CKD STAGES 3 AND 4 WITH HYPERPARATHYROIDISM NOT ON DIALYSIS (ENROLLMENT COMPLETE) (Sanofi)	Secondary Hyperparathyroidism Chronic Kidney Disease	5-18	Doxercalciferol (GZ427397)	15-59
SAFETY AND EFFICACY OF APR2020 IN CKD STAGE IV (Kibow)	Chronic Kidney Disease Stage IV	18-80	US-APR2020	15-29
PREVENTION OF ARTERIOVENOUS GRAFT THROMBOSIS AND SAFETY OF MK-2060 IN PATIENTS WITH ESRD RECEIVING HEMODIALYSIS (Merck Sharpe & Dohme)	End Stage Renal Disease & Kidney Failure	18+	MK-2060	N/A

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.



NEPHCURE
Kidney International

This is a living document and was last updated on 7/18/22.

Trial Table Updated Monthly on NephCure.org/TrialTable

You Can Make New C3G Treatments Possible

CLINICAL TRIALS FOR C3G PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
FREEDOM-2 (Talaris)	De novo living donor transplant (3-12 months after transplant)	18+	FCR001	N/A
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18-75	Extracorporeal photopheresis	N/A
AUTOLOGOUS REGULATORY T CELL INFUSION AND ZORTRESS IN RENAL TRANSPLANT RECIPIENTS (Novartis)	De novo living donor transplant	18-65	Apheresis	N/A
STUDY OF VIB4920 AND BELATACEPT FOR PROPHYLAXIS OF ALLOGRAFT REJECTION IN KIDNEY TRANSPLANT (ENROLLMENT COMPLETE) (Horizon Therapeutics/Viela Bio)	De novo transplant	18-70	VIB4920 & Belatacept	N/A
T CELL MODULATION IN KIDNEY TRANSPLANTATION WITH BIOLOGIC BLOCKADE OF DUAL EFFECTOR PATHWAYS, CD28 & IL-6 (CTOT-24) (ENROLLMENT COMPLETE) (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
STEADFAST (Sangamo Therapeutics)	Kidney transplant rejection	18-70	TX200-TR101	N/A

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.

This is a living document and was last updated on 7/18/22.



NEPHCURE[®]
Kidney International

You Can Make New C3GN Treatments Possible

CLINICAL TRIALS FOR C3GN PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
THE NOBLE STUDY (Apellis)	C3GN, C3G, DDD, MPGN, or IC-MPGN that has recurred after kidney transplant	18+	Pegcetacoplan	≥ 15
VALIANT (Apellis)	C3GN, C3G, IC-MPGN, DDD, MPGN	12+	Pegcetacoplan	≥ 30
THE DISCOVERY TRIAL (ENROLLMENT COMPLETE) (Apellis)	C3GN, C3G, IC-MPGN, DDD, MPGN	18+	Pegcetacoplan	≥ 30
STUDY TO TEST EFFECT OF DIFFERENT DOSES OF BI 685509 ON KIDNEY FUNCTION IN CKD WITHOUT DIABETES (Boehringer Ingelheim)	Chronic Kidney Disease	18+	BI 685509	≥ 20 & < 90
STUDY OF AZD5718 IN PROTEINURIC CKD (AstraZeneca)	Chronic Kidney Disease	18+	AZD5718, Dapagliflozin	20-75
ZENITH-CKD (AstraZeneca)	Chronic Kidney Disease	18+	Zibotentan Dapagliflozin	≥ 20
EAGLE (Reata)	Chronic Kidney Disease, Alport Syndrome	12+	Bardoxolone methyl	≥ 20
FIONA - STUDY OF FINERENONE IN ADDITION TO AN ACEI OR ARB FOR CHILDREN 6 MONTHS TO < 18 YEARS OF AGE WITH CKD (Bayer)	Chronic Kidney Disease	6 months to 17 years	Finerenone (Kerendia, BAY94-8862)	≥ 30
FIND-CKD (Bayer)	Chronic Kidney Disease	18+	Finerenone (BAY94-8862)	≥ 25 and < 90
STUDY OF HECTOROL IN PEDIATRIC PATIENTS WITH CKD STAGES 3 AND 4 WITH HYPERPARATHYROIDISM NOT ON DIALYSIS (ENROLLMENT COMPLETE) (Sanofi)	Secondary Hyperparathyroidism Chronic Kidney Disease	5-18	Doxercalciferol (GZ427397)	15-59
SAFETY AND EFFICACY OF APR2020 IN CKD STAGE IV (Kibow)	Chronic Kidney Disease Stage IV	18-80	US-APR2020	15-29
PREVENTION OF ARTERIOVENOUS GRAFT THROMBOSIS AND SAFETY OF MK-2060 IN PATIENTS WITH ESRD RECEIVING HEMODIALYSIS (Merck Sharpe & Dohme)	End Stage Renal Disease & Kidney Failure	18+	MK-2060	N/A
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
FREEDOM-2 (Talaris)	De novo living donor transplant (3-12 months after transplant)	18+	FCR001	N/A

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.



NEPHCURE
Kidney International

This is a living document and was last updated on 7/18/22.

[Trial Table Updated Monthly on NephCure.org/TrialTable](https://NephCure.org/TrialTable)

You Can Make New C3GN Treatments Possible

CLINICAL TRIALS FOR C3GN PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18-75	Extracorporeal photopheresis	N/A
AUTOLOGOUS REGULATORY T CELL INFUSION AND ZORTRESS IN RENAL TRANSPLANT RECIPIENTS (Novartis)	De novo living donor transplant	18-65	Apheresis	N/A
STUDY OF VIB4920 AND BELATACEPT FOR PROPHYLAXIS OF ALLOGRAFT REJECTION IN KIDNEY TRANSPLANT (ENROLLMENT COMPLETE) (Horizon Therapeutics/Viela Bio)	De novo transplant	18-70	VIB4920 & Belatacept	N/A
T CELL MODULATION IN KIDNEY TRANSPLANTATION WITH BIOLOGIC BLOCKADE OF DUAL EFFECTOR PATHWAYS, CD28 & IL-6 (CTOT-24) (ENROLLMENT COMPLETE) (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
STEADFAST (Sangamo Therapeutics)	Kidney transplant rejection	18-70	TX200-TR101	N/A

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.

This is a living document and was last updated on 7/18/22.



NEPHCURE[®]
Kidney International

You Can Make New MPGN Treatments Possible

CLINICAL TRIALS FOR MPGN PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
THE NOBLE STUDY (Apellis)	MPGN, IC-MPGN, C3GN, C3G, or DDD, or any of these conditions that has recurred after kidney transplant	18+	Pegcetacoplan	≥ 15
VALIANT (Apellis)	MPGN, IC-MPGN, C3G, C3GN, DDD	12+	Pegcetacoplan	≥ 30
STUDY OF ANG-3070 IN PRIMARY GLOMERULAR DISEASE (Angion)	Glomerular Disease	18+	ANG-3070	≥ 40
STUDY TO TEST EFFECT OF DIFFERENT DOSES OF BI 685509 ON KIDNEY FUNCTION IN CKD WITHOUT DIABETES (Boehringer Ingelheim)	Chronic Kidney Disease	18+	BI 685509	≥ 20 & < 90
STUDY OF AZD5718 IN PROTEINURIC CKD (AstraZeneca)	Chronic Kidney Disease	18+	AZD5718, Dapagliflozin	20-75
ZENITH-CKD (AstraZeneca)	Chronic Kidney Disease	18+	Zibotentan Dapagliflozin	≥ 20
EAGLE (Reata)	Chronic Kidney Disease, Alport Syndrome	12+	Bardoxolone methyl	≥ 20
FIONA - STUDY OF FINERENONE IN ADDITION TO AN ACEI OR ARB FOR CHILDREN 6 MONTHS TO < 18 YEARS OF AGE WITH CKD (Bayer)	Chronic Kidney Disease	6 months to 17 years	Finerenone (Kerendia, BAY94-8862)	≥ 30
FIND-CKD (Bayer)	Chronic Kidney Disease	18+	Finerenone (BAY94-8862)	≥ 25 and < 90
STUDY OF HECTOROL IN PEDIATRIC PATIENTS WITH CKD STAGES 3 AND 4 WITH HYPERPARATHYROIDISM NOT ON DIALYSIS (ENROLLMENT COMPLETE) (Sanofi)	Secondary Hyperparathyroidism Chronic Kidney Disease	5-18	Doxercalciferol (GZ427397)	15-59
SAFETY AND EFFICACY OF APR2020 IN CKD STAGE IV (Kibow)	Chronic Kidney Disease Stage IV	18-80	US-APR2020	15-29
PREVENTION OF ARTERIOVENOUS GRAFT THROMBOSIS AND SAFETY OF MK-2060 IN PATIENTS WITH ESRD RECEIVING HEMODIALYSIS (Merck Sharpe & Dohme)	End Stage Renal Disease & Kidney Failure	18+	MK-2060	N/A
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
FREEDOM-2 (Talaris)	De novo living donor transplant (3-12 months after transplant)	18+	FCR001	N/A

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.



This is a living document and was last updated on 7/18/22.

Trial Table Updated Monthly on NephCure.org/TrialTable

You Can Make New MPGN Treatments Possible

CLINICAL TRIALS FOR MPGN PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18-75	Extracorporeal photopheresis	N/A
AUTOLOGOUS REGULATORY T CELL INFUSION AND ZORTRESS IN RENAL TRANSPLANT RECIPIENTS (Novartis)	De novo living donor transplant	18-65	Apheresis	N/A
STUDY OF VIB4920 AND BELATACEPT FOR PROPHYLAXIS OF ALLOGRAFT REJECTION IN KIDNEY TRANSPLANT (ENROLLMENT COMPLETE) (Horizon Therapeutics/Viela Bio)	De novo transplant	18-70	VIB4920 & Belatacept	N/A
T CELL MODULATION IN KIDNEY TRANSPLANTATION WITH BIOLOGIC BLOCKADE OF DUAL EFFECTOR PATHWAYS, CD28 & IL-6 (CTOT-24) (ENROLLMENT COMPLETE) (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
STEADFAST (Sangamo Therapeutics)	Kidney transplant rejection	18-70	TX200-TR101	N/A

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.

This is a living document and was last updated on 7/18/22.



NEPHCURE[®]
Kidney International

You Can Make New Treatments Possible

CLINICAL TRIALS FOR TRANSPLANT PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
FREEDOM-2 (Talaris)	De novo living donor transplant (3-12 months after transplant)	18+	FCR001	N/A
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18-75	Extracorporeal photopheresis	N/A
AUTOLOGOUS REGULATORY T CELL INFUSION AND ZORTRESS IN RENAL TRANSPLANT RECIPIENTS (Novartis)	De novo living donor transplant	18-65	Apheresis	N/A
STUDY OF VIB4920 AND BELATACEPT FOR PROPHYLAXIS OF ALLOGRAFT REJECTION IN KIDNEY TRANSPLANT (ENROLLMENT COMPLETE) (Horizon Therapeutics/Viela Bio)	De novo transplant	18-70	VIB4920 & Belatacept	N/A
THE NOBLE STUDY (Apellis)	MPGN, IC-MPGN, C3GN, C3G, or DDD, or any of these conditions	18+	Pegcetacoplan	≥ 15
VALIANT (Apellis)	MPGN, IC-MPGN, C3G, C3GN, DDD	12+	Pegcetacoplan	≥ 30
POST-APPROVAL STUDY OF LIPOSORBER LA-15 SYSTEM FOR PEDIATRIC & DRUG RESISTANT ADULT PATIENTS WITH FSGS (Kaneka)	Post-transplant recurrent FSGS or Primary FSGS	5-75	Liposorber LA-15 System	≥ 45 or post-transplant recurrence
T CELL MODULATION IN KIDNEY TRANSPLANTATION WITH BIOLOGIC BLOCKADE OF DUAL EFFECTOR PATHWAYS, CD28 & IL-6 (CTOT-24) (ENROLLMENT COMPLETE) (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	1 & 2
STEADFAST (Sangamo Therapeutics)	Kidney transplant rejection	18-70	TX200-TR101	1 & 2

Visit [KidneyHealthGateway.com](https://www.kidneyhealthgateway.com) to play your part in cutting-edge kidney research.

This is a living document and was last updated on 7/18/22.



NEPHCURE[®]
Kidney International

You Can Make New Treatments Possible

CLINICAL TRIALS FOR PEDIATRIC PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
EPPIK (Traverse)	FSGS, MCD, IgAN, IgAV, Alport Syndrome	1-17	Sparsentan	≥ 30
DUPLEX (ENROLLMENT COMPLETE) (Traverse)	FSGS	8-75	Sparsentan	≥ 30
VALIANT (Apellis)	C3G, IC-MPGN, C3GN, DDD, MPGN	12+	Pegcetacoplan	≥ 30
POST-APPROVAL STUDY OF LIPOSORBER LA-15 SYSTEM FOR PEDIATRIC & DRUG RESISTANT ADULT PATIENTS WITH FSGS (Kaneka)	Post-transplant recurrent FSGS or Primary FSGS	5-75	Liposorber LA-15 System	≥ 45 or post- transplant recurrence
TUMOR NECROSIS FACTOR INHIBITION IN FSGS AND TREATMENT-RESISTANT MCD (University of Michigan)	FSGS, MCD	6-70	adalimumab	> 45
EAGLE (Reata)	Chronic Kidney Disease, Alport Syndrome	12+	Bardoxolone methyl	≥ 20
FIONA - STUDY OF FINERENONE IN ADDITION TO AN ACEI OR ARB FOR CHILDREN 6 MONTHS TO < 18 YEARS OF AGE WITH CKD (Bayer)	Chronic Kidney Disease	6 months to 17 years	Finerenone (Kerendia, BAY94-8862)	≥ 30
STUDY OF HECTOROL IN PEDIATRIC PATIENTS WITH CKD STAGES 3 AND 4 WITH HYPERPARATHYROIDISM NOT ON DIALYSIS (ENROLLMENT COMPLETE) (Sanofi)	Secondary Hyperparathyroidism Chronic Kidney Disease	5-18	Doxercalciferol (GZ427397)	15-59

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.

This is a living document and was last updated on 7/18/22.



NEPHCURE[®]
Kidney International